Negotiating renal dysfunction when treating patients with heart failure. (1st February 2018)

• Record Type: Journal Article
• Authors: Carubelli, Valentina; Metra, Marco; Lund, Lars H.
• Is Part Of: Expert review of cardiovascular therapy. Volume 16:Number 2(2018)
• Page Start: 113
• Page End: 122
• Publication Date: 2018-02-01
• Subjects: Heart failure -- renal dysfunction -- chronic kidney disease -- treatment; Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1080/14779072.2018.1422178
• Languages: English
• ISSNs: 1477-9072

Abstract

ABSTRACT: Introduction : Chronic kidney disease (CKD) is one of the most prevalent comorbidities in HF, and no specific treatment is still available for the so-called cardiorenal syndrome. Areas covered : The aim of this review is to describe the interaction of heart and kidney function and the consequences of cardiorenal syndrome, focusing on the use of available therapeutics. Expert commentary : The presence of CKD has been associated with adverse outcomes in HF regardless of ejection fraction. On the other hand, cardiovascular events are the most common causes of morbidity and mortality among CKD patients, reflecting the close pathophysiological crosstalk between these organs. Multiple mechanisms are involved in the development of cardiorenal syndrome, including hemodynamic, neurohormonal and inflammatory mediators. The management of several HF drugs is a challenge in the presence of CKD mainly due to blunted diuretic response and increased risk of worsening of kidney function. Therefore, finding a balance between the optimization of cardiac and renal outcomes is a real negotiation in the everyday clinical practice.